Provided by Tiger Fintech (Singapore) Pte. Ltd.

Applied Therapeutics Inc.

0.3440
+0.01143.43%
Post-market: 0.34410.0001+0.03%19:58 EDT
Volume:4.50M
Turnover:1.51M
Market Cap:48.70M
PE:-0.45
High:0.3480
Open:0.3300
Low:0.3210
Close:0.3326
Loading ...

RBC downgrades Applied Therapeutics as FDA rejects Govorestat, hacks price target

Investing.com
·
29 Nov 2024

Update: Applied Therapeutics' Shares Fall After FDA Rejects NDA for Govorestat in Classic Galactosemia

MT Newswires Live
·
29 Nov 2024

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of US Farm Prices Data

MT Newswires Live
·
29 Nov 2024

Top Premarket Decliners

MT Newswires Live
·
29 Nov 2024

Applied Therapeutics CRL a ‘major setback,’ says William Blair

TIPRANKS
·
29 Nov 2024

Stock Track | Applied Therapeutics Plunges 71.76% Pre-market as RBC Downgrades, Slashes Price Target

Stock Track
·
29 Nov 2024

U.S. RESEARCH ROUNDUP-Applied Therapeutics, Brown-Forman, Ulta Beauty

Reuters
·
29 Nov 2024

Applied Therapeutics Inc : Baird Cuts Target Price to $5 From $14

THOMSON REUTERS
·
29 Nov 2024

RBC Downgrades Applied Therapeutics to Sector Perform From Outperform, Cuts Price Target to $4 From $12, Keeps Speculative Risk

MT Newswires Live
·
29 Nov 2024

Applied Therapeutics Inc : RBC Cuts to Sector Perform From Outperform; Cuts Target Price to $4 From $12

THOMSON REUTERS
·
29 Nov 2024

Applied Therapeutics Shares Drop 73.1% Premarket After U.S. FDA Declines to Approve Co's Genetic Disease Drug

THOMSON REUTERS
·
29 Nov 2024

24H|Nvidia and ASML Rise 1%; MicroStrategy Gains 4%; Archer Aviation Jumps 10%; Applied Therapeutics Plunges 74%

Tiger Newspress
·
29 Nov 2024

APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDA

Zacks
·
28 Nov 2024

BRIEF-Applied Therapeutics Receives Complete Response Letter From U.S. FDA Regarding New Drug Application For Govorestat

Reuters
·
28 Nov 2024

Applied Therapeutics Down 76% After Hours on FDA Complete Response Letter

Dow Jones
·
28 Nov 2024

BUZZ-Applied Therapeutics plummets after FDA declines to approve genetic disease drug

Reuters
·
28 Nov 2024

US FDA Rejects Applied Therapeutics' New Drug Application for Govorestat in Classic Galactosemia

MT Newswires Live
·
28 Nov 2024

Applied Therapeutics Shares Down 82.73% at $1.48 in Extended Trade After US FDA Declines to Approve Genetic Disease Drug

THOMSON REUTERS
·
28 Nov 2024

Applied Therapeutics trading resumes

TIPRANKS
·
28 Nov 2024

Applied Therapeutics Receives FDA Complete Response Letter for Govorestat New Drug Application

Dow Jones
·
28 Nov 2024